Safety And Efficacy Of Rifabutin In Patients For Non-HIV Patients

CompletedOBSERVATIONAL
Enrollment

628

Participants

Timeline

Start Date

November 30, 2008

Primary Completion Date

July 31, 2016

Study Completion Date

July 31, 2016

Conditions
TuberculosisNon-tuberculous Mycobacterial Diseases (Including MAC Disease)
Interventions
DRUG

rifabutin

"Mycobutin® capsules150mg depending on the Investigator prescription. Frequency and duration are according to Package Insert as follows. 1.Tuberculosis : The usual adult dosage for oral use is 150 mg to 300 mg of rifabutin once daily.For the treatment of multiple-drug resistance tuberculosis, the usual dosage for oral use is 300 to 450 mg of rifabutin once daily.~2.Treatment of non-tuberculous mycobacterial diseases (including MAC disease) : The usual adult dosage for oral use is 300 mg of rifabutin once daily."

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT00810407 - Safety And Efficacy Of Rifabutin In Patients For Non-HIV Patients | Biotech Hunter | Biotech Hunter